Vivek Ramaswamy is a prominent entrepreneur and investor whose wealth comes from his biotech ventures and investments.
If you’re curious about Vivek Ramaswamy’s net worth and how he accumulated his fortune, you’re in the right place.
In this article, we’ll break down his wealth, salary, financial milestones, and key business ventures, including his role in Roivant Sciences and Strive Asset Management.
Vivek Ramaswamy Quick Facts
| FACT | DETAIL |
|---|---|
| Real Name | Vivek Ganapathy Ramaswamy |
| Popular Name | Vivek Ramaswamy |
| Birth Date | August 9, 1985 |
| Age | 40 years (as of 2025) |
| Birthplace | Cincinnati, Ohio, USA |
| Nationality | American |
| Ethnicity | Indian (Parents from Kerala, India) |
| Education | Yale Law School (2013), Harvard University (2007), St. Xavier High School (2003) |
| Marital Status | Married |
| Spouse | Apoorva T Ramaswamy (m. 2015) |
| Children | 2 sons |
| Dating | Married to Apoorva |
| Siblings | N/A |
| Parents | Vivek Ganapathy (father) & Geeta Ramaswamy (mother) |
| Height (m) | N/A |
| Net Worth | $1.1 Billion |
| Source of Wealth | Biotech, financial investments, entrepreneurship, and authorship |
What is the Net Worth of Vivek Ramaswamy in 2025?
As of 2025, Vivek Ramaswamy’s net worth is estimated at $1.1 billion. This is a significant sum, placing him among the most successful entrepreneurs in the biotech and investment sectors.
When compared to other figures in the business and biotech world, Vivek’s wealth positions him as a key player.
His net worth is similar to other entrepreneurs like Peter Thiel, Mark Zuckerberg, and Eli Lilly, all of whom made their fortune through biotech or tech ventures.
However, it’s important to note that his wealth isn’t just from investments but also from his ventures like Roivant Sciences, which sold drugs worth billions, and his stake in Strive Asset Management.
Here are a few people/companies related to Vivek Ramaswamy:
- Peter Thiel
- Mark Zuckerberg
- Eli Lilly
- Roivant Sciences
- Strive Asset Management
- Axovant Sciences
- Sumitomo Dainippon
- Campus Venture Network
- QVT Financial
For more on wealth and financial rankings, check out our richest people section.
Vivek Ramaswamy Wealth, Salary and Financial Overview
How Did Vivek Ramaswamy Build His Wealth?
Vivek Ramaswamy’s wealth began to take shape with his pioneering work in the biotechnology industry. After completing his education at Harvard and Yale, Ramaswamy entered the world of finance and biotech, first co-founding Campus Venture Network and later working at QVT Financial.
However, his wealth took a significant turn when he founded Roivant Sciences in 2014. Roivant became known for acquiring underperforming drug candidates and developing them into profitable products. His 7% stake in Roivant played a significant role in building his wealth.
Additionally, Ramaswamy made a splash in 2020 when Roivant sold five drugs to Sumitomo Dainippon for $3 billion, earning him a reported $176 million.
With continued investments in biotech and pharmaceuticals, Ramaswamy was able to expand his financial portfolio into other companies, including Strive Asset Management, a venture that focuses on index funds, which has seen rapid growth in valuation.
Vivek Ramaswamy’s Salary and Earnings Over the Years
Vivek Ramaswamy’s salary is difficult to pinpoint exactly, as much of his wealth stems from his investments and stakes in companies rather than traditional salary-based earnings.
During his time as CEO of Roivant Sciences, Ramaswamy’s compensation would have included a mix of salary, equity, and performance-based bonuses. After stepping down as CEO, Ramaswamy’s salary likely decreased, but his earnings from the sale of Roivant’s drugs and his stake in Strive Asset Management ensured his wealth continued to grow.
Apart from his biotech ventures, Ramaswamy has earned money through public speaking and publishing. His books, such as Woke, Inc. and Nation of Victims, have contributed to his financial standing and have increased his media presence, adding another revenue stream to his earnings.
What Are Vivek Ramaswamy’s Investments and Business Ventures?
Ramaswamy’s primary investment success comes from his biotech ventures, particularly Roivant Sciences.
But his entrepreneurial portfolio doesn’t stop there. After his success with Roivant, he co-founded Strive Asset Management, a company focused on providing index funds to investors. This has contributed significantly to his growing wealth, with Strive’s valuation estimated at $300 million in 2023.
Other ventures include Axovant Sciences, a biotech company that focused on gene therapies, and Chapter Medicare, which focuses on healthcare-related services. While some of these ventures have not been as successful, they still reflect Ramaswamy’s broad investment interests and willingness to take risks in high-growth sectors.
Ramaswamy is also known for his philosophy of prioritizing excellence in business and pushing back against corporate social justice movements, which has helped him build a unique brand that resonates with many business-minded individuals.
Key Financial Milestones in Vivek Ramaswamy’s Career
Roivant Sciences: Founded in 2014, Roivant Sciences quickly became a major player in the biotech industry. The company’s strategic acquisitions of underperforming drug candidates, like those sold to Sumitomo Dainippon, led to financial success for Ramaswamy.
Strive Asset Management: The co-founding of Strive Asset Management in 2021 allowed Ramaswamy to expand his wealth into the asset management industry. The company’s rapid valuation increase has helped secure his place among top entrepreneurs in the financial sector.
$176 Million Earnings from Roivant: In 2020, Roivant Sciences sold five drugs to Sumitomo Dainippon for $3 billion. Ramaswamy’s 7% stake in the company earned him an estimated $176 million.
Conclusion
Vivek Ramaswamy has built an impressive fortune from his entrepreneurial ventures, particularly in the biotech and asset management sectors. From founding Roivant Sciences to co-founding Strive Asset Management, his financial journey is a testament to smart investments and strategic risk-taking.
For more insights on finance and celebrity wealth, feel free to leave a comment, share this article, or explore more on AndoMoney.
